Compare CFND & RKTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFND | RKTO |
|---|---|---|
| Founded | N/A | 2017 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4M | 18.9M |
| IPO Year | 2024 | 2018 |
| Metric | CFND | RKTO |
|---|---|---|
| Price | $2.59 | $0.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.6K | ★ 247.2K |
| Earning Date | N/A | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.69 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.04 | $0.48 |
| 52 Week High | $7.90 | $1.19 |
| Indicator | CFND | RKTO |
|---|---|---|
| Relative Strength Index (RSI) | 39.93 | 32.20 |
| Support Level | $2.56 | N/A |
| Resistance Level | $3.48 | $0.77 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 3.87 | 17.19 |
C1 Fund Inc is a non-diversified, closed-end management investment company. The Adviser provides day-to-day investment management services to the Company, which is classified as non-diversified under the Investment Company Act. The Company's investment objective is to maximize its portfolio's total return by principally investing in privately held equity and equity-linked securities of digital asset services and technology companies. Its investments in equity securities include common and preferred shares, securities convertible into common shares, warrants and rights to subscribe to or purchase common shares, and common shares carrying a warrant or right.
Rocket One Inc is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic AI chip technology designed for radiation-tolerant, energy-constrained environments such as low-Earth orbit, deep-space platforms, and defense systems. The company also intends to pursue opportunities related to nano-launch systems and nanosatellite deployment. In addition, its biotechnology operations, conducted through a wholly owned subsidiary, include development programs such as HT-001, HT-KIT, HT-ALZ, and a GDNF-based metabolic program.